FDA finally approves Amylin's once-a-week diabetes injection

Share this article:

The third time was the charm for Amylin Pharmaceuticals' once-a-week diabetes injection drug. Bydureon was approved Friday, following two prior rejections. Amylin executives say the new drug's convenient regimen will give it a competitive advantage in the marketplace. Diabetes affects more than 25 million people in the U.S., including many nursing facility residents.


Share this article:

More in Products

Higher rates of mortality seen with benzodiazepine sedatives, study says

Continuous infusion benzodiazepines, a group of sedatives often used to treat intensive-care unit patients on ventilators, are linked to an increased likelihood of death compared to those who received propofol, a new study says.

Drive Medical introduces long-term care beds

Drive Medical introduces long-term care beds

Drive Medical is offering four new long-term care beds, including two models designed with the bariatric resident in mind.

New footwear sanitizing system released

New footwear sanitizing system released

Best Sanitizers Inc. has announced the HACCP SmartStep™ Footwear Sanitizing System. The system reduces cross-contamination from footwear for employees working in labs, clean rooms or in pharmaceutical plants.